2023
DOI: 10.3390/ijerph20021095
|View full text |Cite
|
Sign up to set email alerts
|

Impact of Metformin on Periodontal and Peri-Implant Soft and Hard Tissue

Abstract: Periodontal and peri-implant soft and hard tissue in diabetic patients have always been a topic of interest for researchers and clinicians alike. Among which, a subtopic that has attracted more attention is the beneficial effect of metformin (MF) on periodontal and peri-implant soft and hard tissue. This review aimed to assess the impact of MF on the periodontal and peri-implant soft- and hard-tissue healing among diabetic patients. Research was conducted using the keywords ‘metformin’, ‘diabetes’, ‘periodonti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 48 publications
0
3
0
Order By: Relevance
“…In addition, patients with diabetes are three times more likely to develop periodontitis (Aljofi et al, 2023;Preshaw & Bissett, 2013).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, patients with diabetes are three times more likely to develop periodontitis (Aljofi et al, 2023;Preshaw & Bissett, 2013).…”
Section: Discussionmentioning
confidence: 99%
“…Patients with type 2 diabetes may be at increased risk for postoperative complications due to infection or slow wound healing. In addition, patients with diabetes are three times more likely to develop periodontitis (Aljofi et al, 2023 ; Preshaw & Bissett, 2013 ). Antidiabetic drugs such as metformin have been shown to have a beneficial effect on bone tissue, acting on osteoblasts and reducing the risk of fractures in patients with diabetes (Bak et al, 2010 ; Cortizo et al, 2006 ).…”
Section: Discussionmentioning
confidence: 99%
“…[ 297 ] Metformin, commonly prescribed for type 2 diabetes patients, reduces the inflammatory response and oxidative stress and stimulates osteoblastic activity. [ 298 ] Alendronate, a bisphosphonate often used to treat osteoporosis, effectively suppresses bone resorption and possesses anti‐inflammatory properties. [ 299 ] In clinical trials, they have been administered as hydrogels, with a concentration of 1.2% for statins and 1% for alendronate and metformin, demonstrating improvements in clinical and radiographic parameters.…”
Section: Discussionmentioning
confidence: 99%